Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

References

• Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infiiximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451–8.
   PubMedGoogle Scholar
• Choy EHS, Isenberg DA, Ganood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. 2002;46:3143–50.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with human-ized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORP: significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-con-trolled trial. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanised anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106: 2627–32.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371: 998–1006.
   PubMed Web of Science ®Google Scholar
• Guideline for the use of tocilizumab in rheumatoid arthritis, Japan College of Rheumatology home page (in Japanese). http://www. ryumachi-jp.com/info/080724_TCZ.html.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Study Group of the Ministry of Health, Labour and Welfare. Diagnostic and therapeutic manual of rheumatoid arthritis. Diagnostic manual and evidence-based treatment guidelines (in Japanese). Tokyo: Japan Rheumatism Foundation; 2004.
   Google Scholar
• Kawai S, Yamamoto K. Safety of tacrolimus, an immunosup-pressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology. 2006;45:441–4.
   PubMed Web of Science ®Google Scholar
• Kawai S, Tanaka K, Ohno I, Utsunomiya K, Seino Y. Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. Mod Rheuma-tol. 2008;18:345–53.
   Google Scholar
• Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol. 2005;15:91–6.
   Google Scholar
• Kishimoto T. Interleukin-6: discovery of apleiotropic cytokine. Arthritis Res Ther. 2006;8(Suppl 2):52.
   Google Scholar
• Ogawa J, Harigai M, Akashi T, Nagasaka K, Suzuki F, Tominaga S, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanized anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis. 2006;65:1667–9.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheu-matic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.
   Google Scholar
• Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflunbeil S, Mac-hold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res 'Ther. 2005;7:R796–806.
   Google Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Romos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371: 987–97.
   Google Scholar
• Genovese MC, Mckay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with toc-ilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58: 2968–80.
   Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2008; (Epub ahead of print).
   Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with inflix-imab, a tumor necrosis factor a-neutralizing agent. N Engl J Med. 2001;345:1098–104.
   Google Scholar
• Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19:64–8.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
   PubMed Web of Science ®Google Scholar
• Tsuru T, Terao K, Suzaki M, Nakashima H, Amamoto T, Akiyama A, et al. Immune response to influenza vaccine in patients with rheumatoid arthritis under IL-6 signal blockade therapy with tocilizumab. Ann Rheum Dis. 2007;66(Suppl II):439.
   Google Scholar
• Tsuru T, Terao K, Suzaki M, Nakashima H, Amamoto T, Akiyama A, et al. Immune response to Pneumococcal vaccine in patients with rheumatoid arthritis under IL-6 receptor inhibition with tocilizumab. Arthritis Rheum. 2007;56:S1026.
   Google Scholar
• Chugai Pharmaceuticals Ltd. Safety Report of Actemra. November 2008 (in Japanese).
   Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2007;67:189–94.
   PubMedGoogle Scholar
• Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Safety outcomes from a large Japanese post-marketing surveillance for etanercept. Arthritis Rheum. 2007;56:5182.
   Google Scholar
• Yoon DY, Chu J, Chandler C, Hiyama S, Thompson JE, Hines 0J. Human cytokine levels in nonperforated versus perforated appendicitis: molecular serum markers for extent of disease? Am Surg. 2002;68:1033–7.
   Google Scholar
• Endo S, Inada K, Inoue Y, Otsu T, Kasai T, Kuwata Y, et al. Endotoxin and cytokines in patients with gastrointestinal tract perforation. Mediators Inflamm. 1992;1:45–8.
   Google Scholar
• Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient Marker of injury or mediator of inflammation? Ann Surg. 1996;224:647-64.
   Google Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Catsleman disease. Blood. 2008;112: 3959–64.
   PubMed Web of Science ®Google Scholar
• Dubinsky V, Junovich G, Gentile T, Gutierrez G. IL-6 as a reg-ulatory factor of the humoral response during pregnancy. Am J Reprod Immunol. 2008;60:197–203.
   Google Scholar
• Yamanaka H, Nishimoto N, Inoue E, Hara M, Tomatsu T, Kamatani N. Incidence of malignancies in Japanese rheumatoid arthritis patients treated with tocilizumab in comparison to those in an observational cohort Japanese patients and a Japanese population database. Ann Rheum Dis. 2007;66(Suppl II):122.
   Google Scholar
• Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. Implications for translational therapeutics. Cancer. 2007;110: 1911–28.
   Google Scholar